Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Yizhong Pharmaceutical Co (SHSE:688091) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shanghai Yizhong Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥7,321.9 Mil.
Shanghai Yizhong Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥62.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Yizhong Pharmaceutical Co EV-to-EBIT Related Terms
Shanghai Yizhong Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Yizhong Pharmaceutical Co EV-to-EBIT Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Yizhong Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Yizhong Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Yizhong Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shanghai Yizhong Pharmaceutical Co's EV-to-EBIT falls into.
Shanghai Yizhong Pharmaceutical Co's current Enterprise Value is ¥7,610.4 Mil.
Shanghai Yizhong Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥62.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Yizhong Pharmaceutical Co (SHSE:688091) has a EV-to-EBIT of 121.57 as of Sep. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Yizhong Pharmaceutical Co and its competitors. This is 47% above median its historical median of 82.80. According to the industry distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #649 out of 684 companies in the Drug Manufacturers industry, placing it in the top 94.9%.
Is Shanghai Yizhong Pharmaceutical Co's EV-to-EBIT too high?
Shanghai Yizhong Pharmaceutical Co's current EV-to-EBIT of 121.57 is 47% above median its 10-year median of 82.80. The Drug Manufacturers industry median EV-to-EBIT is 15.84. Shanghai Yizhong Pharmaceutical Co's value of 121.57 is 667.5% above this industry median. Based on the distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #649 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Yizhong Pharmaceutical Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Yizhong Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #649 out of 684 companies for EV-to-EBIT. This places Shanghai Yizhong Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBIT is 15.84. Shanghai Yizhong Pharmaceutical Co's value of 121.57 is 667.5% above this benchmark. While the company's 10-year median is 82.80 vs. the industry median of 15.84, Shanghai Yizhong Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.84, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Yizhong Pharmaceutical Co's current EV-to-EBIT of 121.57 is 667.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Yizhong Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Yizhong Pharmaceutical Co's current EV-to-EBIT is 121.57, which is 47% above median its own 10-year median of 82.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Yizhong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Yizhong Pharmaceutical Co (SHSE:688091) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥43.01, compared to a current price of ¥38.83 — trading 9.7% below its estimated fair value. The current EV-to-EBIT is 121.57, which is 47% above median its 10-year median of 82.80 and 667.5% above the Drug Manufacturers industry median of 15.84. Shanghai Yizhong Pharmaceutical Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shanghai Yizhong Pharmaceutical Co (SHSE:688091), the current EV-to-EBIT is 121.57 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Yizhong Pharmaceutical Co (SHSE:688091) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Yizhong Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥38.83 is trading 9.7% below its estimated GF Value™ of ¥43.01.
GuruFocus considers Shanghai Yizhong Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688091:
EV-to-EBIT: 121.57 (47% above median its 10-year median of 82.80)
GF Value™: ¥43.01 vs. price of ¥38.83 (9.7% below fair value)
Industry Position: 667.5% above the Drug Manufacturers median (#649 of 684)
No single metric tells the full story. See the SHSE:688091 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Yizhong Pharmaceutical Co Ltd is a pharmaceutical enterprise integrating research and development, production and sales. It is committed towards the development of new dosage forms of anti-tumor drugs and related products.
57GF Score
Get the complete analysis for SHSE:688091
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688091 has been successfully added to your 
